Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology.

ABSTRACT: While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide clinical management based on molecular biomarkers. To this end, we have structured a compendium of approved and experimental therapies with associated biomarkers following a survey of drug regulatory databases, existing knowledge bases, and published literature. Each biomarker-disease-therapy triplet was categorised using a tiering system reflective of key therapeutic considerations: approved and reimbursed therapies with respect to a jurisdiction (Tier 1), evidence of efficacy or approval in another jurisdiction (Tier 2), evidence of antitumour activity (

SUBMITTER: Lin FP 

PROVIDER: S-EPMC8222322 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature